111 related articles for article (PubMed ID: 7742602)
1. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma].
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Bull Cancer; 1994 Jul; 81(7):599-604. PubMed ID: 7742602
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines.
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Eur J Cancer; 1993; 29A(16):2269-73. PubMed ID: 8110498
[TBL] [Abstract][Full Text] [Related]
3. [Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].
Fischel JL; Formento P; Berlion M; Berille J; Gioanni J; Bizzari JP; Milano G
Bull Cancer; 1992; 79(1):81-90. PubMed ID: 1520955
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
5. Guide-lines in the design of new antiestrogens and cytotoxic-linked estrogens for the treatment of breast cancer.
Leclercq G; Devleeschouwer N; Heuson JC
J Steroid Biochem; 1983 Jul; 19(1A):75-85. PubMed ID: 6887875
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Cancer Res; 1993 Apr; 53(7):1571-6. PubMed ID: 8453625
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antiproliferative effects of the combination of interleukin-1 alpha and doxorubicin against human melanoma cells.
Mimnaugh EG; Monti E; Sebers S; Stetler-Stevenson M; Sinha BK
Oncol Res; 1992; 4(10):401-12. PubMed ID: 1292755
[TBL] [Abstract][Full Text] [Related]
8. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
9. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036.
Tapiero H; Yin MB; Catalin J; Paraire M; Deloffre P; Rustum Y; Bizzari JP; Tew KD
Anticancer Res; 1989; 9(6):1617-22. PubMed ID: 2627116
[TBL] [Abstract][Full Text] [Related]
11. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
12. Activity of platinum drugs against melanoma cell lines: is it modulated in vitro in the presence of tamoxifen?
Mohammed MQ; Photiou A; Shah P; Retsas S
Anticancer Res; 1995; 15(4):1319-26. PubMed ID: 7654015
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
14. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
15. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptors in human myeloma cells.
Otsuki T; Yamada O; Kurebayashi J; Moriya T; Sakaguchi H; Kunisue H; Yata K; Uno M; Yawata Y; Ueki A
Cancer Res; 2000 Mar; 60(5):1434-41. PubMed ID: 10728710
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
19. Brief tamoxifen pretreatment enhances the chemosensitivity of gastric carcinoma cells to 5-fluorouracil in vitro.
Koullias GJ; Pratsinis CI; Korkolis DP; Kouraklis G; Papadopoulos SA; Davaris PS; Golematis BCh
Anticancer Res; 2003; 23(2B):1575-80. PubMed ID: 12820425
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness and safety of combined mustoforan, cisplatin and tamoxifen for disseminated cutaneous melanoma (results of the IC4-10036-46-RU trial)].
Konstantinova MM; Gershanovich ML; Akimov MA; Nosov DA; Bogdanova NV
Vopr Onkol; 2005; 51(5):550-7. PubMed ID: 16756009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]